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A B S T R A C T  
 
Introduction: Neurofascin, encoded by NFASC, is a transmembrane protein that plays an essential role in nervous system 
development and node of Ranvier function. Anti-Neurofascin autoantibodies cause a specific type of chronic inflammatory 
demyelinating polyneuropathy (CIDP) often characterized by cerebellar ataxia and tremor. Recently, homozygous NFASC 
mutations were recently associated with a neurodevelopmental disorder in two families. 
 
Methods: A combined approach of linkage analysis and whole-exome sequencing was performed to find the genetic cause of 
early-onset cerebellar ataxia and demyelinating neuropathy in two siblings from a con-sanguineous Italian family. Functional 
studies were conducted on neurons from induced pluripotent stem cells (iPSCs) generated from the patients. 
 
Results: Genetic analysis revealed a homozygous p.V1122E mutation in NFASC. This mutation, affecting a highly conserved 
hydrophobic transmembrane domain residue, led to significant loss of Neurofascin protein in the iPSC-derived neurons of 
affected siblings. 
Conclusions: The identification of NFASC mutations paves the way for genetic research in the developing field of 
nodopathies, an emerging pathological entity involving the nodes of Ranvier, which are associated for the first time with a 
hereditary ataxia syndrome with neuropathy.  
 
 
 
 
 
 
1. Introduction 
 
Neurofascin, a member of the L1 immunoglobulin cell adhesion molecule 
family (L1CAM) family, is a transmembrane protein, encoded by NFASC, an 
evolutionarily conserved gene located on chromosome 1q32, and ubiquitously 
expressed in human tissues [1]. Neurofascin protein is abundant in the adult 
central nervous system, especially in the cerebellum and peripheral nerves 
[2,3]. Moreover, Neurofascin plays a pivotal role in the development and 
function of the axon initial segment (AIS) and the nodes of Ranvier [4,5]. 
Both the AIS and node of Ranvier contain a high density of sodium voltage-
gated channels, ne-cessary for action potential generation and propagation, 
which are clustered by interactions with several cytoskeletal and scaffolding 
 
 
 
 
 
 
proteins, including Neurofascin. Another recognized role of Neurofascin is to 
connecting the extracellular matrix and glial cells (Schwann cells and 
oligodendroglia) with the intracellular skeleton of neurons [6–8].  
NFASC transcripts undergo extensive alternative splicing and pro-tein 
isoforms are differentially expressed in the central and peripheral nervous 
systems in a developmental- and cell type-specific manner. In the adult 
mouse, Neurofascin has two principal isoforms: the neuronal isoform (138 
kDa), known as NF186, and the glial isoform (133 kDa), known as NF155. 
These proteins are highly glycosylated with observed molecular weights on 
Western blot of 186 kDa and 155 kDa respectively [9,10]. Similarly, adult 
human nervous tissues have two principal Neurofascin isoforms with 
molecular weights of 186 kDa and 150 kDa.  
Here, we describe two affected siblings from a consanguineous 
  
 
 
  
Italian family presenting with infantile-onset ataxia and mild demye-linating 
polyneuropathy who carry a homozygous NFASC missense mutation. 
 
 
2. Materials and methods 
 
2.1. Clinical data 
 
Patients were subjected to general and neurological examination by an 
ataxia-experienced neurologist. Both affected individuals underwent brain 
MRI and neurophysiological studies. Blood samples were col-lected. The 
Ethics Committee of the IRCCS Foundation Ca’ Granda Ospedale Maggiore 
Policlinico (Milan, Italy) approved the study. Written informed consent was 
obtained from all involved subjects. 
 
2.2. Genetic analysis 
 
Genomic DNA was extracted from peripheral venous blood from all 
family members by standard salting-out procedures. All subjects were 
genotyped using the Infinium OmniExpressExome-8 v1.3 BeadChip array, 
which includes a total of 958,497 markers, with a mean spacing of 3.03 kb. A 
multipoint parametric linkage analysis was performed using Allegro software 
to identify chromosomal loci compatible with recessive inheritance (Used 
map: Illumina 650 k HumanHap v3 deCODE; Inheritance: Recessive; 
Penetrance: 99%; Scoring function: HOMOZ and MNAllele). 
 
Individual II.1 (see Fig. 1) was analyzed by whole exome sequencing 
(WES) starting from 50 ng of genomic DNA using the Nextera Rapid Capture 
Exome Library kit (Illumina, San Diego, CA, USA) and the Il-lumina 
NextSeq500 platform (Illumina) according to the manufacturer instructions. 
Reads were aligned against the human reference genome (hg19) using BWA 
[11]. Variant calling was performed with GATK [12] and variant annotation 
with ANNOVAR (http://annovar. openbioinformatics.org/en/latest/). The 
candidate variants and their 
  
 
segregation in the family were validated by Sanger sequencing. Primers used 
for PCR amplification and Sanger sequencing of NFASC and NSMCE4A are 
listed in Supplementary Table 1.  
Array comparative genomic hybridization (array-CGH) was per-formed 
using an Agilent SurePrint G3 human 4 × 180 K kit. Data were analyzed 
using CytoGenomics 3.0 (Agilent Technologies, Santa Clara, CA, USA). 
Aberrations were considered when the involved genomic region was covered 
by at least three adjacent probes and all arrays showed a derivative log ratio 
(DLR) spread < 0.2. Genomic co-ordinates were based on the 37 build 
(February 2009) of the Human Genome Reference Consortium 
(GRch37/hg19). 
 
2.3. Cell cultures 
 
Skin punch biopsies were obtained from the ventral part of the left 
forearm of both affected siblings. Fibroblasts were cultured in DMEM high 
glucose supplemented with 15% fetal bovine serum (Euroclone, Milan, Italy), 
1% penicillin/streptomycin (Sigma-Aldrich, Saint Louis, MO, USA), and 1% 
of amphotericin B (Sigma-Aldrich).  
Fibroblasts were reprogrammed to induced pluripotent stem cells (iPSCs) 
using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Life Technologies, 
Carlsbad, CA, USA). Clones with an iPSC-like mor-phology underwent 
karyotype analysis, and those carrying a normal karyotype were used for 
differentiation (Supplementary Fig. 1A). IPSCs were differentiated to fully 
mature neurons using the method described by Zhang et al. [13] 
(Supplementary Table 2 and Supplementary Figs. 1B–C). 
 
 
2.4. Immunocytofluorescence 
 
Immunocytofluorescence studies were performed according to standard 
protocols. The iPSCs and neurons were stained with primary antibodies 
detecting Sox 2 (ab15830, Abcam, Cambridge, UK), Neurofascin (ab31457, 
Abcam), β-tubulin III (T8660, Sigma-Aldrich), 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Family pedigree, clinical features, and brain MRI. A) Pedigree of the family under study. Black symbols denote affected individuals. B) Clinical characteristics of subjects II.1 
and II.2 (”+” = presence, “-” = absence, “−/+” = intermediate features). C) Brain MRI of subjects II.1 and II.2 (sagittal T1 on the left and axial T2 on the right) performed at 22 and 15 
years of age respectively, showing mild atrophy of the cerebellar vermis in subject II.1 and a mild diffuse T2 hyperintensity of white matter, probably due to hypomyelination, in both 
probands. 
 
  
and MAP2 (M9942, Sigma-Aldrich). Alexa Fluor 488 and Alexa Fluor 594 
were used as secondary antibodies (Life Technologies). Images were acquired 
using a Leica SP5 confocal microscope system (Leica Biosystems, Wetzlar, 
Germany). ImageJ software was used to assess fluorescence intensity [14]. 
 
 
2.5. Protein blotting and sub-cellular fractionation 
 
Whole-protein lysates were obtained by standard methods. Subcellular 
fractionation was performed using the Subcellular Protein Fractionation Kit 
for Cultured Cells (Thermo Fisher Scientific, Waltham, MA, USA) according 
to the manufacturer's instructions. Fraction-spe-cific markers were evaluated 
by Western blot (α-tubulin for cytoplasm; COX-IV for cell and mitochondrial 
membranes). Western blot analyses were performed in triplicate according to 
standard procedures using the following primary antibodies: Neurofascin 
(ab31457, Abcam); α-tu-bulin (MCA3560Z, AbD Serotec, Kidlington, UK), 
COX-IV (A21348, Life Technologies), actin (A2066, Sigma-Aldrich). The 
anti-Neurofascin an-tibody is directed against the intracellular domain of the 
protein and detects different protein isoforms in human brain (e.g. NF186 and 
NF155) (Fig. 4A). 
 
 
2.6. Data availability 
 
The data that support the findings of this study are available from the 
corresponding author, upon reasonable request. 
 
3. Results 
 
3.1. Clinical features 
 
The family originated from an isolated valley of Northern Italy. The 
parents (subjects I.1 and I.2) were first cousins (Fig. 1A). The two af-fected 
siblings were 22 (subject II.1) and 15 (subject II.2) years old at first 
examination. The probands presented an early psychomotor delay and the 
younger brother exhibited a mild intellectual disability. They started to walk 
at 3 years of age with an unsteady wide-based ataxic gait. Cerebellar 
dysarthria, intention tremor, dysmetria, pursuit sacca-dization, and 
dysdiadochokinesia were also observed. Eye closing did not worsen ataxic 
features, suggesting a primary cerebellar involve-ment. 
 
From the age of 11 years, subject II.1 developed progressive spastic 
hypertonia of the limbs with hyperreflexia, lower limbs intra-rotation, ankle 
clonus, and bilateral Babinski sign. A therapeutic challenge with baclofen 
(per os and intrathecal) was not successful. At 16 years of age, she started to 
use a wheelchair outside the house and required bilateral support for standing. 
In addition, remarkable sleepiness in the morning appeared, which responded 
well to modafinil (50 mg die). Mild dys-phagia was demonstrated at 18 years 
of age. At 24 years old, she de-veloped involuntary sub-continuous non-
rhythmic myoclonic jerks in the proximal upper limbs, which disappeared 
during sleep and were aggravated by anxiety and emotions. 
 
Subject II.2 did not develop hypertonia of the limbs or hyperre-flexia. 
From the age of 12 years, he had episodes of aggression and intense anxiety, 
associated with reality detachment and perseverations. Partial remission of 
these episodes was achieved with low doses of ar-ipiprazole and paroxetine. 
 
Brain MRI showed mild atrophy of the cerebellum in the older sibling and 
a mild diffuse T2 hyperintensity of periventricular white matter in both 
probands, probably due to brain hypomyelination (Fig. 1C). 
Electroencephalography (EEG) showed bilateral fronto-tem-poral slowing in 
both probands. The involuntary movements of subject II.1 were not 
associated with EEG abnormalities. Motor evoked poten-tials (MEPs) showed 
a marked slowing of the central conduction velo-city in both the upper and 
lower limbs. Somatosensory evoked poten-tials (SEPs) showed a mild to 
moderate slowing of the central 
  
 
conduction velocity. Pattern shift visual evoked potentials (VEPs) were 
within normal limits in II.2, but they could not be reliably assessed in II.1 
because of artefacts due to the continuous involuntary movements. However, 
flash VEPs could be assessed and their latency appeared to be mildly 
increased. Nerve conduction studies showed a mild length-de-pendent 
demyelinating sensory-motor peripheral neuropathy, which was more evident 
in II.2 than in II.1 (Supplementary Table 3). The sensory contribution to 
ataxia was considered to be of minor im-portance considering that the 
neuropathy was mild and not evident at the neurological examination, the 
central and peripheral sensory tracts and fibers were less involved than the 
motor counterparts, and closing the eyes did not worsen the ataxic features. 
 
Muscle biopsies performed on both siblings were unremarkable. Ocular 
fundus examinations were normal. No cardiological abnormal-ities were 
found. Standard blood tests were normal. 
 
3.2. Genetic analysis 
 
SCA1, SCA2, SCA3, SCA6, SCA8, SCA10, SCA12, SCA17, DRPLA, 
and Friedreich's ataxia pathological expansions were ruled out. Screening for 
mutations in SPG4, SPG7, SPG11, SPG15, SPG35, SETX, ARSACS, 
SCA28, and PLA2G6 was negative. Karyotype and array-CGH were normal. 
The family pedigree and consanguinity of the parents strongly suggested an 
autosomal recessive pattern of inheritance, with a homozygous mutation 
being suspected as the cause of the disease.  
Linkage analysis identified two haploidentical homozygous regions in the 
two affected individuals on chromosomes 1 and 10 (Fig. 2A). Flanking 
markers of the homozygous regions were rs4951272-rs11572795 for 
chromosome 1 and rs2765471-rs716909 for chromo-some 10. A single gene 
known to be involved in genetic ataxias was present in the linked regions, 
SYT14 located on chromosome 1 and coding for synaptotagmin XIV. 
However, no variants were found in the patients by Sanger sequencing of 
SYT14 exons and intron-exon boundaries. 
 
WES was performed on subject II.1, obtaining and a mean coverage depth 
of 76.1 with 92% of the bases of the target region having ≥20x coverage 
(97.5% with coverage ≥10x). No pathogenic mutations were found in known 
disease genes for hereditary ataxias, spastic para-plegias, or neuropathies. A 
filtering analysis for rare (allele fre-quency < 1%) variants with protein impact 
(missense, nonsense, fra-meshift, inframe ins/del, nonstop, misstart, splice 
disruptive) was performed in the homozygous linkage regions. Only two 
novel homo-zygous variants were identified: c.3365 T > A, p.V1122E in 
NFASC (NM_001005388), and c.754–5_754-4delTT in NSMCE4A 
(NM_001167865, coding for NSMCE4a protein). The mutations were 
confirmed to be homozygous in subjects II.1 and II.2 and heterozygous in 
both parents by Sanger sequencing (Fig. 2B and Supplementary Fig. 2A). 
 
 
The NSMCE4A c.754–5_754-4delTT is a novel variant near the splicing 
acceptor site of exon 6. The deleted nucleotides are not con-served in 
mammals and, in contrast to NFASC, NSMCE4A is not pre-ferentially 
expressed in nerve tissue, but rather in the bladder, colon, uterus, and prostate. 
Moreover, Mutation Taster and CADD did not predict this variant to be 
deleterious. NSMCE4A is tolerant to loss of function mutations (probability 
of being loss-of-function intolerant [pLI] 0.09, ExAC Browser) in contrast to 
the extremely intolerant pLI value of 1.0 for NFASC. However, analysis of 
the patients’ cDNA showed a higher expression of an alternative spliced 
transcript due to skipping exon 6 (XR_001747116.1) in addition to the normal 
transcript (NM_001167865) (Supplementary Figs. 2B–C), and a possible con-
tribution to the disease cannot be ruled out. 
 
The p.V1122E NFASC mutation is a novel variant absent from public 
databases. The valine at position 1122 is highly conserved in ortholo-gous 
proteins and lies in the unique Neurofascin transmembrane do-main, which is 
present in all protein isoforms. Substitution with a hy-drophilic glutamic acid 
(Fig. 2C) is expected to affect the 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Genetic and bioinformatic analysis. A) Linkage analysis plot displaying LODscore values at different chromosomal regions (multipoint parametric analysis, scoring function: 
HOMOZ). Two peaks on chromosomes 1 and 10 indicate haploidentical homozygous regions in the two affected siblings. B) Electropherograms of the NFASC c.3693 T > A 
homozygous mutation in the probands (II.1 and II.2) and the heterozygous mutation in their parents (I.1 and I.2). C) Alignment of Neurofascin protein homologs showing conservation 
of the amino acid mutated in this family (Valine 1122). The colors represent those used in the ClustalW multiple sequence alignment program [27]. Each residue in the alignment is 
assigned a color if the amino acid profile at that position meets the minimum criteria specific for the residue type (blue = hydrophobic, magenta = positively charged, red = negatively 
charged, green = polar, cyan = aromatic, pink = cysteines, or-ange = glycines, yellow = prolines). D) Assessment of the deleterious impact of the NFASC p.V1122E variant by in silico 
prediction tools SIFT, Provean, Polyphen2, Mutation Taster, Condel, and CADD. (For interpretation of the references to color in this figure legend, the reader is referred to the Web 
version of this article.) 
 
transmembrane domain leading to impaired Neurofascin stability and 
function. Pathogenicity prediction tools SIFT, Provean, Polyphen2, Condel, 
Mutation Taster, and CADD were used to assess the impact of the identified 
variant. The NFASC p.V1122E mutation was predicted by all prediction tools 
to be deleterious (Fig. 2D). The cDNA analysis did not show a reduced 
amount of NFASC transcript in patients compared to controls. 
 
Therefore, NFASC was prioritized as the candidate etiological gene in 
this family. To assess this hypothesis, functional studies were per-formed on 
iPSC-derived neurons. 
 
3.3. Cellular and protein studies 
 
Fibroblasts from the two affected siblings and three healthy controls were 
cultured from skin biopsies. Because Neurofascin is not expressed in 
fibroblasts, they were reprogrammed to iPSCs and then differentiated into 
mature neurons. Immunocytofluorescence (ICF), performed at 50 days in vitro 
(DIV) showed a discrete Neurofascin distribution within controls neuron 
somata and several smaller spots of staining in neu-ronal somata and 
extensions (Fig. 3A–B). Neurofascin immuno-fluorescence was significantly 
reduced in patients (Student's t-test, p = 0.005; Fig. 3C). Antibodies against 
the intracellular domain of Neurofascin exhibit cytoplasmic staining, 
representing the endosome-localized fraction of the protein [15]. A 
remarkable loss of Neurofascin was detected in neuronal cell bodies of 
patients, with less intense and more scattered staining (Fig. 3). 
 
Immunoblotting neuronal lysates resulted in a single band at ap-
proximately 150 kDa and a significant reduction in the amount of Neurofascin 
protein (approximately to half of controls) in both patients compared to 
controls (Student's t-test, p = 0.0058; Fig. 4B–C).  
Interestingly, immunoblotting Neurofascin in iPSC-derived neurons 
 
resulted in a single band at ∼150 kDa, which is the predicted size of the 
longest protein isoform in humans. However, in adult human nerve tissue, 
protein glycosylation of Neurofascin results in observed mole-cular weights 
of 186 kDa and 155 kDa (Fig. 4A), corresponding to the neuronal and glial 
isoforms respectively. This molecular weight dis-crepancy may be explained 
by a different pattern of glycosylation in cultured cells [16] or by the 
expression of an alternative NFASC splicing isoform in iPSC-derived 
neurons.  
Subcellular fractionation of cultured neurons showed prevalent membrane 
localization of Neurofascin, as expected [17], and a strong reduction of the 
protein in the membrane of patient-derived cells compared to controls 
(Student's t-test, p = 0.005; Fig. 4D–E). 
 
4. Discussion 
 
We found a novel NFASC homozygous missense mutation in two siblings 
presenting with progressive infantile-onset ataxia with de-myelinating 
neuropathy. The variant causes the substitution of a hy-drophobic amino acid 
with a hydrophilic amino acid in the single transmembrane domain of the 
Neurofascin protein, suggesting a highly deleterious effect of the mutation. 
The functional studies described here are strongly consistent with NFASC 
being the most potential candidate gene, showing a significant reduction of 
the Neurofascin protein in iPSC-derived neurons from patients. However, a 
contribution of the splice variant of NSMCE4A remains plausible and 
requires further in-vestigation. 
 
Considering that the amount of NFASC mRNA is not decreased in 
patients’ neurons, the reduction in Neurofascin is probably due to protein 
instability in membranes and accelerated turnover. Neurofascin is known to 
localize in the neuronal body, specifically at the level of the endo-lysosomal 
compartment. This would explain the punctate staining 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. ICF studies of iPSC-derived neurons. A-B) Skin biopsy-derived fibroblasts from the two affected siblings (II.1 and II.2) and three healthy controls (only CTR1 and CTR2 are 
shown) were reprogrammed into iPSCs and then differentiated into neurons. Confocal microscopy analysis showed discrete Neurofascin distribution (green) within control neuron 
somata and several spots of staining in neuronal extensions, whereas a remarkable loss and more scattered cytoplasmic staining of Neurofascin was detected in patients (bottom). 63x 
magnification (A) and 63× 2×-zoom magnification (B). C) Immunofluorescence quantification confirmed the statistically significant reduction of Neurofascin fluorescence in patients. * = 
p < 0.01. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
 
 
in ICF analysis, which is strongly reduced and scattered in neurons from 
patients, in line with the significant reduction in Neurofascin on Western blot 
analysis.  
Neurofascin plays an essential role in central and peripheral nervous 
system development and function; therefore, it is biologically plausible that 
dysfunction of this protein can cause a composite neurological disorder. 
Previously described NFASC knockout mouse models have been reported to 
have a neurological phenotype with important nodal and paranodal 
involvement. NF155-null mouse mutants exhibit severe ataxia, motor paresis, 
and reduced nerve conduction velocities, with a mean survival of 
approximately 3 weeks. In these mice, paranodal ax-oglial junctions fail to 
form, and myelinated axons undergo degenera-tion [18,19]. NFASC mutants 
lacking both the glial NF155 and neuronal NF186 died at post-natal day 6 and 
exhibited an extensive disruption of the nodal-paranodal region in the central 
and peripheral nervous sys-tems, a strong reduction of nerve conduction 
velocities, and delayed/ reduced myelination of the central nervous system 
[7,9].  
Two NFASC homozygous mutations (NM_001160331.1: c.1109G > C: 
p.R370P and c.2536C > T: p.R846X) were recently proposed as the cause of a 
severe neurodevelopmental disorder in two families [20,21]. The disease 
presented a highly pleiotropic clinical phenotype, variably characterized by 
global developmental delay, hy-pertonia or hypotonia, neonatal respiratory 
distress, intellectual dis-ability, areflexia, and facial dysmorphic features 
(hypertelorism, high and wide nasal bridge, micrognathia, glossoptosis, and 
cleft palate). Remarkably, brain MRI performed on one affected subject 
showed 
 
 
diffuse white matter T2 hyperintensity [21].  
Smigiel et al. [20] reported immunofluorescence staining of skin biopsies 
from the probands, revealing an absence of the NF155 isoform at the 
paranode of myelinated axons and the disruption of the nodal axoglial 
complex. Localization of the mutation in an exon present only in the 
transcript encoding NF155 explains the specific absence of the glial isoform. 
 
The variable clinical phenotype may be caused by several factors: the 
severity of the mutation, the selective involvement of distinct Neurofascin 
isoforms by pathogenic variants, and the presence of ge-netic modifiers. In 
any case, the intra-familial and inter-familial phe-notypic heterogeneity 
suggests a broad clinical spectrum associated with biallelic NFASC 
mutations. The description of additional cases is warranted in order to better 
define the NFASC-associated clinical phe-notypes. 
 
Neurofascin is well known to clinical neurologists because a sig-nificant 
proportion of chronic inflammatory demyelinating poly-neuropathies (CIDPs) 
are caused by IgG4 antibodies against NF155 [22]. These cases are often 
associated with cerebellar ataxia and tremor  
[23]. Neuropathology on nerve biopsies shows minimal demyelination and a 
predominant injury to the nodes of Ranvier, which has prompted some 
authors to introduce the concept of nodopathy [24]. The nodes of Ranvier are 
ubiquitously present in myelinated structures of the central and peripheral 
nervous systems, including the cerebellum. The pheno-types associated with 
NFASC mutations clearly highlight the involve-ment of the central nervous 
system [20,21]. We propose expanding the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Immunoblot studies of iPSC-derived neurons. A) Immunoblot with anti-Neurofascin antibody comparing iPSC-derived neurons with an adult human brain. In iPSC-derived 
neurons, there is a single band at ∼150 kDa, different from the bands at 155 and 186 kDa in the adult human brain. B-C) Immunoblots of neuronal lysates demonstrate a single band at 
∼150 kDa and a significant reduction of Neurofascin protein (approximately to half of the controls) in both patients (II.1 and II.2) compared to controls (CTR1, CTR2, and CTR3). D-E) 
Subcellular fractionation of cultured neurons showed prevalent membrane localization of Neurofascin and a strong reduction of the protein in the membranes of patient-derived cells 
compared to controls (p = 0.005). α-Tubulin and COX-IV are cytosol and membrane-fraction markers respectively. M = membrane, C = cytosol, * = p < 0.05, ** = p < 0.01. 
 
 
concept of nodopathy to central nervous system involvement, as there can be 
combined central and peripheral demyelination in anti-Neuro-fascin 
autoantibodies syndromes [22]. 
The neurophysiological results in the two affected siblings revealed 
slowing of the central and peripheral conduction velocities with more severe 
involvement of the central nervous system than the peripheral nervous 
system, and of motor fibers than sensory fibers, without con-duction blocks, 
which are described as a common finding in acquired nodopathies [24]. The 
specific clinical neurophysiological features of patients with hereditary 
Neurofascin-related nodopathy could depend on the damaging potential of the 
causative mutation [25] and could be different from what is typically observed 
in acquired nodopathy [24], similarly to the differences commonly 
encountered between hereditary and acquired demyelinating polyneuropathies 
[26]. The issue of the neurophysiological spectrum of patients with genetic 
nodopathy should be addressed in future patients to better describe the 
pathophysiology and genotype-phenotype correlation. 
 
In conclusion, the identification of NFASC as a causative gene for ataxia 
with demyelinating neuropathy paves the way for genetic re-search in the 
developing field of Neurofascin-related nodopathies of the central and 
peripheral nervous system. 
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